Botulinum Toxin Use for Modulating Neuroimmune Cutaneous Activity in Psoriasis

• Published in: Medicina (Kaunas, Lithuania) Vol. 58; no. 6; p. 813
• Main Authors: Popescu, Marius Nicolae, Beiu, Cristina, Iliescu, Mădălina Gabriela, Mihai, Mara Mădălina, Popa, Liliana Gabriela, Stănescu, Ana Maria Alexandra, Berteanu, Mihai
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 16.06.2022; MDPI
• Subjects: Alopecia; Antigens; Baldness; Botulinum toxin; Cytokines; Dermatitis; Disease; Hyperactivity; Hyperhidrosis; Immune system; Inflammation; Nervous system; neurogenic inflammation; neuroimmune system; Neuropeptides; Pathogenesis; Proteins; Psoriasis; Remission (Medicine); Review; Rosacea; Spasticity; Stroke
• ISSN: 1648-9144; 1010-660X; 1648-9144
• DOI: 10.3390/medicina58060813

Psoriasis is a complex immune-mediated inflammatory disorder that generates enormous interest within the scientific communities worldwide, with new therapeutic targets being constantly identified and tested. Despite the numerous topical and systemic medications available for the treatment of psoriasis, alternative therapies are still needed for the optimal management of some patients who present with localized, resistant lesions. Novel insights into the contribution of cutaneous neurogenic inflammation in the pathogenesis of psoriasis have yielded exciting new potential roles of nerve-targeting treatments, namely botulinum toxin type A (BoNT-A), for the management of this disease. This paper aims to review the existing literature on knowledge regarding the potential role of BoNT-A in psoriasis treatment, with a focus on its ability to interfere with the immunopathogenetic aspects of psoriatic disease. Furthermore, in our paper, we are also including the first report of psoriatic lesions remission following local BoNT-A injections that were administered for treating upper limb spasticity, in a patient that concomitantly suffered from psoriasis and post-stroke spasticity.